81. Amyotrophic Lateral Sclerosis - Health And Medical Information Produced By Docto Doctorproduced health and medical information written for you to make informed decisions about your health concerns. http://www.medicinenet.com/amyotrophic_lateral_sclerosis/article.htm

document.writeln(''); MedicineNet Home > Amyotrophic Lateral Sclerosis search help Printer-Friendly Format FREE Newsletters Email to a Friend ... Next Amyotrophic Lateral Sclerosis (ALS or "Lou Gehrig's Disease") What is amyotrophic lateral sclerosis? What are the types of ALS? What are symptoms of ALS and how is it diagnosed? How is ALS treated? What is amyotrophic lateral sclerosis? Amyotrophic lateral sclerosis (also called ALS or "Lou Gehrig's disease") is a classic motor neuron disease. Motor neuron diseases are progressive chronic diseases of the nerves that come from the spinal cord responsible for supplying electrical stimulation to the muscles. This stimulation is necessary for the movement of body parts. ALS is progressive and fatal. The usual causes of death of patients with motor neuron diseases are not directly related to the disease, but result from simultaneous additional illnesses which ultimately occur because of weakness of the body. These illnesses are often infections. ALS occurs most often in adults in the fifth through seventh decades of life. It progressively leads to death in 2 to 7 years. The cause is unknown.

82. National Registry Of Veterans With Amyotrophic Lateral Sclerosis The Department of Veterans Affairs (VA) is developing a nationwide registry of living veterans who have amyotrophic lateral sclerosis (ALS). http://hsrd.durham.med.va.gov/alsregistry.asp

Center for Health Services Research in Primary Care Path: ALS Registry National Registry of Veterans with ALS Center for Health Services Research in Primary Care Fellowship Opportunities Recent Research Funding Organizational Ties ... Research Program Affiliations A National VA Initiative (DVA Cooperative Study #500A) The Department of Veterans Affairs (VA) is developing a nationwide registry of living veterans who have amyotrophic lateral sclerosis (ALS). This effort is directed by the Epidemiologic Research and Information Center (ERIC) at the VA Medical Center in Durham, NC, with cooperation from the VA Medical Center in Lexington, KY. The ALS Association (ALSA) is advising the study leaders. All living veterans who have been diagnosed with ALS are encouraged to participate in this research registry. What is ALS? ALS, also known as Lou Gehrig’s disease, is a chronic and progressive neurodegenerative disease that attacks the brain cells that control muscle movement. As these cells die, the affected muscles weaken and then shrink, leading to progressive paralysis. There are no known cures for this disease. ALS is a non-contagious, adult-onset disease and is rare among individuals under 45 years of age. What is the purpose of this registry?

83. NORD - National Organization For Rare Disorders, Inc. amyotrophic lateral sclerosis (ALS) is one of a group of disorders known as motor neuron diseases Organizations related to amyotrophic lateral sclerosis http://www.rarediseases.org/search/rdbdetail_abstract.html?disname=Amyotrophic L

84. Amyotrophic Lateral Sclerosis amyotrophic lateral sclerosis (ALS) is a terminal neurological disorder characterized by Currently, there is no cure for amyotrophic lateral sclerosis. http://medicalcenter.osu.edu/patientcare/healthinformation/diseasesandconditions

Skip Navigation home about us referring ... Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis (ALS) What is amyotrophic lateral sclerosis (ALS)? Amyotrophic lateral sclerosis (ALS) is a terminal neurological disorder characterized by progressive degeneration of nerve cells in the spinal cord and brain. Often referred to as "Lou Gehrig's disease" (a famous baseball player who died from the disease), it is one of the most devastating of the disorders that affects the function of nerves and muscles. ALS does not affect mental functioning or the senses (such as seeing or hearing), and it is not contagious. Currently, there is no cure for amyotrophic lateral sclerosis. Statistics of ALS: Consider the following statistics regarding ALS: Most people who develop ALS are between the ages of 40 and 70, although the disease can occur at a younger age. ALS occurs throughout the world with no racial, ethnic, or socioeconomic boundaries. ALS affects as many as 30,000 Americans, with 5,600 new cases diagnosed in the US each year. What are the different types of ALS?

85. Les Turner ALS Foundation - ALS amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig s disease, is a neuromuscular disorder that causes progressive paralysis and ends in death. http://www.lesturnerals.org/als.htm

What Is ALS? Resource Guide Informative Links Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a neuromuscular disorder that causes progressive paralysis and ends in death. ALS causes a degeneration of the motor neurons in the brain and spinal cord. When these cells die, it is impossible for the brain to signal voluntary muscle control. People with ALS may experience muscle weakness and impaired speaking, swallowing and breathing; and eventually total paralysis and death. In most cases, the mind remains sharp and alert. ALS Facts Each day, 15 people are newly diagnosed with ALS ALS occurs throughout the world regardless of racial, ethnic or socioeconomic status. ALS typically strikes adults between 40 and 70 years of age. On average, people with ALS die within two to five years from diagnosis. Although many of the symptoms of ALS are treatable, there is no cure. Current treatment is aimed at symptomatic relief, prevention of complications, and maintenance of maximum optimal function and quality of life. Contact Us Site Map Join Our Mailing List Les Turner ALS Foundation 8142 North Lawndale Avenue, Skokie, IL 60076-3322

86. Amyotrophic Lateral Sclerosis (ALS) Detailed information on amyotrophic lateral sclerosis, including statistics, types, symptoms, diagnosis, and treatment. http://www.healthsystem.virginia.edu/uvahealth/adult_neuro/als.cfm

[ Skip Navigation ] Health System Home For Health Answers Healthcare Professionals ... Advanced Search Health System Search Search for Information People UVa Home Health System News Health System Events (all) Health System Publications ... Making a Gift Topics All About Cancer Blood Disorders Bone Disorders Breast Health Cancer Cardiovascular Disease Dermatology Diabetes Digestive Disorders Endocrinology Environmental Medicine Eye Care Glossary Gynecological Health Infectious Diseases Kidney Disease Men's Health Mental Health Nervous System Disorders Non-Trauma Emergency Oral Health Orthopaedics Otolaryngology Pathology Pediatrics, General Health Prostate Health Radiology Respiratory Disorders Skin Cancer Surgical Care Urology Women's Health UVa Health Topics A to Z FIND A DOCTOR Brain Cancer: Medical Oncology Brain Tumors Epilepsy ... WHY CHOOSE UVA Search This Site Amyotrophic Lateral Sclerosis (ALS) What is amyotrophic lateral sclerosis (ALS)? Amyotrophic lateral sclerosis (ALS) is a terminal neurological disorder characterized by progressive degeneration of nerve cells in the spinal cord and brain. Often referred to as "Lou Gehrig's disease" (a famous baseball player who died from the disease), it is one of the most devastating of the disorders that affects the function of nerves and muscles.

87. Treatment For Spasticity In Amyotrophic Lateral Sclerosis/motor Neuron Disease ( Abstract of a systematic review of the effects of health care prepared by the Cochrane Collaboration. http://www.cochrane.org/cochrane/revabstr/AB004156.htm

From The Cochrane Library, Issue 2, 2005 Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease (Cochrane Review) Ashworth NL, Satkunam LE, Deforge D ABSTRACT What's new in this issue Search abstracts Browse alphabetical list of titles Browse by Review Group A substantive amendment to this systematic review was last made on 14 November 2003. Cochrane reviews are regularly checked and updated if necessary. Background: Spasticity commonly affects patients with motor neuron disease and it is likely to contribute to worsening muscle dysfunction, increased difficulty with activities of daily living and deteriorating quality of life. Objectives: The objective of this review is to systematically review all types of treatments for spasticity in amyotrophic lateral sclerosis, also known as motor neuron disease. Search strategy: We searched the Cochrane Neuromuscular Disease Group specialised trials register (searched January 2003), MEDLINE (January 1966 to January 2003), EMBASE (January 1980 to January 2003), CINAHL (January 1982 to January 2003), AMED (January 1985 to January 2003) and LILACS (January 1982 to January 2003) for randomized controlled trials. We reviewed the bibliographies of the randomized trials identified, and contacted trial authors and known experts in the field. Selection criteria: We included quasi-randomized or randomized controlled trials of participants with probable or definite amyotrophic lateral sclerosis according to the El Escorial diagnostic criteria (or a revised version) or the Airlie House revision. We would have included trials of physical therapy, modalities, prescription medications, non-prescription medications, chemical neurolysis, surgical interventions, alternative therapies. Our primary outcome measure was reduction in spasticity at three months or greater as measured by Ashworth (or modified Ashworth) spasticity scale. Our secondary outcome measures were: validated measures based on history, physical examination, physiological measures, measures of function, measures of quality of life, serious adverse events, and measures of cost.

88. Amino Acids For Amyotrophic Lateral Sclerosis / Motor Neuron Disease (Cochrane R Abstract of a systematic review of the effects of health care prepared by the Cochrane Collaboration. http://www.cochrane.org/cochrane/revabstr/AB003457.htm

From The Cochrane Library, Issue 2, 2005 Amino acids for amyotrophic lateral sclerosis / motor neuron disease (Cochrane Review) Parton M, Mitsumoto H, Leigh PN ABSTRACT What's new in this issue Search abstracts Browse alphabetical list of titles Browse by Review Group A substantive amendment to this systematic review was last made on 18 August 2003. Cochrane reviews are regularly checked and updated if necessary. Background: Amyotrophic lateral sclerosis, also known as motor neuron disease, is a progressive neuromuscular disease that causes disability and eventual death. Various amino acid preparations, the three branched-chain amino acids (L-leucine, L-valine and L-isoleucine) or, alternatively, L-threonine have been used as experimental therapy. Objectives: To examine the efficacy of amino acid therapies in prolonging survival and/or slowing the progression of amyotrophic lateral sclerosis/motor neuron disease. Search strategy: We searched the Cochrane Neuromuscular Disease Group trials register (searched February 2003), MEDLINE (from January 1966 to December 2002) and EMBASE (from January 1980 to December 2002) databases and reports of specialist conferences. Authors of known studies were contacted. Selection criteria: We included randomised or quasi-randomised trials of participants with a clinical diagnosis of amyotrophic lateral sclerosis/motor neuron disease treated with all combinations of amino acids. Our primary outcome measure was survival determined by a pooled hazard ratio of all studies. Our secondary outcome measures were (in order of priority): survival at six and 12 months, muscle strength, any validated rating scale of physical function, quality of life, proportion of patients completing therapy and proportion of patients reporting adverse events attributable to treatment.

89. Amyotrophic Lateral Sclerosis CHC Wausau Hospital s Medical Library and Patient Education Center provides research services and healthcare information to physicians, http://www.chclibrary.org/micromed/00037180.html

Main Search Index Definition Description Causes ... Resources Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis (ALS) is caused by the degeneration and death of motor neurons in the spinal cord and brain. These neurons convey electrical messages from the brain to the muscles to stimulate movement in the arms, legs, trunk, neck, and head. As motor neurons degenerate, the muscles are weakened and cannot move as effectively, leading to muscle wasting. (Illustration by Electronic Illustrators Group.) Definition Amyotrophic lateral sclerosis (ALS) is a disease that breaks down tissues in the nervous system (a neurodegenerative disease) of unknown cause that affects the nerves responsible for movement. It is also known as motor neuron disease and Lou Gehrig's disease, after the baseball player whose career it ended. Description ALS is a disease of the motor neurons, those nerve cells reaching from the brain to the spinal cord (upper motor neurons) and the spinal cord to the peripheral nerves (lower motor neurons) that control muscle movement. In ALS, for unknown reasons, these neurons die, leading to a progressive loss of the ability to move virtually any of the muscles in the body. ALS affects "voluntary" muscles, those controlled by conscious thought, such as the arm, leg, and trunk muscles. ALS, in and of itself, does not affect sensation, thought processes, the heart muscle, or the "smooth" muscle of the digestive system, bladder, and other internal organs. Most people with ALS retain function of their eye muscles as well. However, various forms of ALS may be associated with a loss of intellectual function (

90. Important Genetic Risk Factor For Amyotrophic Lateral Sclerosis ? Two Hershey, Pa., researchers were part of a team that has uncovered what may be an important genetic risk factor for amyotrophic lateral sclerosis http://www.news-medical.net/?id=6702

91. Amyotrophic Lateral Sclerosis - Information News A significant proportion of patients suffering from ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig s disease or motor neuron disease, http://www.news-medical.net/?keyword=Amyotrophic lateral sclerosis

92. GeneReviews: Amyotrophic Lateral Sclerosis Overview Your browser does not support HTML frames so you must view amyotrophic lateral sclerosis Overview in a slightly less readable form. http://www.genetests.org/query?dz=als-overview

93. Amyotrophic Lateral Sclerosis amyotrophic lateral sclerosis the term applied to the sporadic and most common form of the disease. Includes a number of overlapping syndromes such as http://www.5mcc.com/Assets/SUMMARY/TP0046.html

Amyotrophic lateral sclerosis DESCRIPTION: A degenerative disease (or group of diseases) which affects the upper and lower motor neurons. Amyotrophic lateral sclerosis: the term applied to the sporadic and most common form of the disease. Includes a number of overlapping syndromes such as pseudobulbar palsy, progressive bulbar palsy, progressive muscular atrophy and primary lateral sclerosis. Familial ALS: an autosomal dominant or recessive disease which is clinically similar to sporadic ALS but probably represents a distinct entity pathologically and biochemically. ALS-Parkinson-dementia complex of Guam: an ALS like syndrome, often, but not always, associated with Parkinson's syndrome and dementia, which is prevalent amongst the Chamorro Indians of Guam (very rare in the USA). System(s) affected: Nervous Genetics: Familial ALS Incidence/Prevalence in USA: 0.4-1.76/100,000 incidence; 5 in 100,000 prevalence Predominant age: Rare before age 40 years. Incidence increases with age. Predominant sex: Male = Female CAUSES: Sporadic ALS - degeneration of the upper and lower motor neurons with their respective axons. Cause is unknown.

94. Amyotrophic Lateral Sclerosis (ALS) - For Patients And Families Center for Human Genetics at Duke University Medical Center researchers search for inherited or genetic causes of ALS which may lead to earlier, http://www.chg.duke.edu/patients/als.html

95. Amyotrophic Lateral Sclerosis Or Lou Gehrig's Disease: Aging Begins At 30: Virtu amyotrophic lateral sclerosis or Lou Gehrig s Disease. Ian Maclean Smith, MD Emeritus Professor Department of Internal Medicine http://www.vh.org/adult/patient/internalmedicine/aba30/2001/lougehrigsdisease.ht

Aging Begins at 30 Amyotrophic Lateral Sclerosis or Lou Gehrig's Disease Ian Maclean Smith, M.D. Emeritus Professor Department of Internal Medicine University of Iowa Hospitals and Clinics Creation Date: June 2001 Last Revision Date: June 2001 Peer Review Status: Internally Peer Reviewed It's amyotrophic because the muscle supplied by the dead nerve cells wastes away; lateral because it affects the side of the spinal cord; and sclerosis because if you feel the cord in that region at autopsy the tissue feels very hard. It's Lou Gehrig's because the record-breaking first baseman and hitter died of it aged 38 in 1941. It is an adult-onset disease first described in France by Charcot in 1874. The disease affects men more than women and usually after age 40. Cells that are motor in function in the brain and spinal cord die and can no longer send messages to the muscles. There are signs of involvement of the brain to cord nerves (upper motor neurons) and of the cord to muscle nerves, (lower motor neurons). Most cases are sporadic, but about 5% occur in affected families. One unusual site for ALS is Guam where the disease is 50 times as prevalent as elsewhere. Viruses and prions have been looked for as a cause and not found. Initially the symptoms are difficulty in swallowing, slurred speech, and painless weakness in the hands or legs. The affected muscles show fasciculations that are rippling contractions seen through the skin or in the tongue. There is no curative treatment, although Rilutek (formerly Riluzole), an anti-glutamate medicine, adds months to patients' lifespan but does not relieve symptoms. At least 14 other drugs have been tested in controlled clinical trials and found to be ineffective. The disease progresses and patients usually die in three to five years, when the muscles controlling breathing fail. The brain, consciousness, eye movements and bladder muscles do not fail.

96. Amyotrophic Lateral Sclerosis World Federation of Neurology amyotrophic lateral sclerosis amyotrophic lateral sclerosis and other motor neuron disorders http://omni.ac.uk/browse/mesh/D000690.html

low graphics Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis / drug therapy Amyotrophic Lateral Sclerosis / genetics broader: Motor Neuron Disease other: Muscular Atrophy, Spinal Poliomyelitis Amyotrophic Lateral Sclerosis International Alliance of ALS/MND Associations The International Alliance of ALS/MND Associations was set up to represent the interests of those with ALS/MND (Motor Neuron Disease and Amyotrophic Lateral Sclerosis. The site includes a Directory of Associations for People with ALS/MND providing details of organisations and groups sharing the Alliance's goals. There is a newsroom page with recent and breaking news on ALS/MND, including research and treatments. Links to other resources are also available. Motor Neuron Disease Amyotrophic Lateral Sclerosis World Federation of Neurology : Amyotrophic Lateral Sclerosis This Web site has links to articles, medical literature reviews, links to patient resources, conferences and meetings, clinical trial updates and abstracts on research and treatment for Amyotrophic Lateral Sclerosis. The site aims to link researchers and clinicians worldwide, and is provided by the World Federation of Neurology ALS Committee. Amyotrophic Lateral Sclerosis Neurology Multiple Sclerosis Motor Neuron Disease ... Amyotrophic lateral sclerosis and other motor neuron disorders Tables of contents and abstracts for the journal Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, which is the official publication of the World Federation of Neurology Research Group on Motor Neuron Disease, from volume 1, Number 1, 1999. The journal covers "all aspects of the diagnosis and management of ALS (Lou Gehrig's disease), primary lateral sclerosis, spinal muscular atrophy and related motor neuron disorders." Full-text access to articles (in PDF, requiring Adobe Acrobat Reader) is available to subscribers, or on a pay-per-view basis. Subscription details are available on the site, as well as a free electronic inspection copy (requiring free registration). Published by Martin Dunitz, part of the Taylor and Francis Group.

97. Amyotrophic Lateral Sclerosis The amyotrophic lateral sclerosis Association requests 1page abstracts for research projects of relevance to ALS. Multiyear grants of up to $60000 for 2 or http://vpr2.admin.arizona.edu/rso/02060513.htm

AMYOTROPHIC LATERAL SCLEROSIS - ALSA The Amyotrophic Lateral Sclerosis Association requests 1-page abstracts for research projects of relevance to ALS. Multiyear grants of up to $60,000 for 2 or 3 years and 1-year starter grants of up to $35,000 for new investigators are available. Contact: Lucie Bruijn, ALSA, 27001 Agoura Rd., Suite 150, Calabasas Hills, CA 91301-5104. Telephone: (818) 880-9007 Fax: (818) 880-9006. E-mail: lucie@alsa-national.org Web: http://www.alsa.org/research/progsci2.cfm Deadline: 1 July 2002 for abstracts. RSO Reference No.:

98. Grand Rounds Archives OTOLARYNGOLOGY ASPECTS OF amyotrophic lateral sclerosis amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder of the motor http://www.bcm.edu/oto/grand/42392.html

Grand Rounds Archives The information contained within the Grand Rounds Archive is intended for use by doctors and other health care professionals. These documents were prepared by resident physicians for presentation and discussion at a conference held at The Baylor College of Medicine in Houston, Texas. No guarantees are made with respect to accuracy or timeliness of this material. This material should not be used as a basis for treatment decisions, and is not a substitute for professional consultation and/or peer-reviewed medical literature. OTOLARYNGOLOGY ASPECTS OF AMYOTROPHIC LATERAL SCLEROSIS Troy Callender, MD April 23, 1992 Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder of the motor neurons. Most of the morbidity and eventual mortality is primarily the result of the bulbar and respiratory involvement by the disease. Otolaryngologists are frequently consulted to participate in the care of ALS patients and will occasionally be the first physician consulted if bulbar symptoms predominate. Pathologic evaluation in ALS shows symmetric demyelinization of the pyramidal columns and loss of anterior horn cells in the spinal cord and in the motor nuclei of the bulb.

99. The DRM WebWatcher: Amyotrophic Lateral Sclerosis (ALS) A Disability Resources Monthly guide to the best online resources about amyotrophic lateral sclerosis (ALS). http://www.disabilityresources.org/ALS.html

Home Subjects States Librarians ... Contact Us The DRM WebWatcher Amyotrophic Lateral Sclerosis (ALS) Updated 7/2004 A B C D ... About/Hint/Link Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neurone disease (MND), is characterised by a progressive degeneration of the motor cells in the brain and spinal cord. The following sites offer useful information about ALS. The ALS Association The website of this nonprofit organization provides information about ALS, news, resources, services, and research information. Most of the association's publications are not online, but may be ordered at no charge by persons with ALS. This section of the "Doctor's Guide" provides links to medical news and alerts, drug information, discussion groups and newsgroups, and more. ALS Survival Guide The Survival Guide is a very extensive personal website by an individual with ALS. The site is well designed and packed with information and links. Topics include ALS news, causes of ALS, statistics, treatments, adaptive equipment, legal/financial, advocacy, ALS Digest, support group, research abstracts, resources, and much more. As always, we recommend viewing medical and legal information on personal websites with caution. Amyotrophic Lateral Sclerosis Fact Sheet This publication from the National Institute of Neurological Disorders and Stroke (NINDS) provides an overview of ALS, including its symptoms, diagnosis, causes, treatment, research, and resources.

100. Amyotrophic Lateral Sclerosis - Demos Medical Publishing amyotrophic lateral sclerosis is an AAN Press Quality of Life Guide and is published by Demos Medical Publishing. http://www.demosmedpub.com/book169.html

246 pages Softcover Regular Price: Discount Price: For related titles see: Amyotrophic Lateral Sclerosis General Neurology Amyotrophic Lateral Sclerosis Robert G. Miller, M.D. Deborah Gelinas, M.D. Patricia O'Connor, RN Sample Chapter: Download Nutrition and Swallowing "Want to know the anatomy and physiology underlying ALS? How the disease is diagnosed? What tests need to be done and what they mean? What clinical trials are all about? How to treat symptoms and live better? How to negotiate the insurance maze? You'll find answers to all these questions and more in this highly readable book" MDA/ALS Newsmagazine "*****!! All of [the authors] have extensive experience helping individuals affected by ALS and their families. Thus, the information they offer in the book is practical, realistic, and specific... All in all, Amyotrophic Lateral Sclerosis provides up-to-date, comprehensive information on living with ALS, which make it very useful for individuals affected by ALS and their families." About.com "Informative, accurate and even reassuring, and will be valuable to readers internationally. In particular, the description of the major features and symptoms caused by ALS is excellent, and the methods of managing these problems are simply and lucidly explained... This book is an excellent and well thought-out example of an important resource that should be made available to all those suffering with ALS." - Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 5     81-100 of 129    Back | 1  | 2  | 3  | 4  | 5  | 6  | 7  | Next 20